PreventaMed s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
PreventaMed s.r.o. is conducting studies aimed at reducing the burden of atherosclerotic cardiovascular disease and related conditions such as hypertension and heart failure.
- Elevated lipoprotein(a) and LDL‑C levels
- High‑risk hypertension
- Heart failure with preserved or mildly reduced ejection fraction
- Major adverse cardiovascular events (MACE)
- Obesity‑related cardiovascular risk
Trials evaluate novel agents like inclisiran, pelacarsen, and retatrutide to test whether they can lower cholesterol, reduce cardiovascular events, or improve heart‑failure outcomes.
Nutritional and Metabolic Diseases
Research at the Olomouc site focuses on metabolic disorders, especially obesity, overweight, and abnormal lipid profiles.
- Obesity and overweight management
- Severe hypertriglyceridemia
- Hypercholesterolemia
- Chronic weight‑management strategies
- Metabolic syndrome components
Innovative therapies such as maridebart cafraglutide, MET097, and KAI‑9531 are being tested for their ability to induce weight loss and improve metabolic biomarkers.
Respiratory Tract Diseases
The facility is active in evaluating treatments for chronic lung conditions, particularly chronic obstructive pulmonary disease.
- Chronic obstructive pulmonary disease (COPD)
- Triple inhaled therapy vs. dual bronchodilator regimens
- Severe cardiopulmonary outcome measures
Studies compare a combination of budesonide, glycopyrronium, and formoterol against standard dual therapy to determine improvements in lung function and cardiovascular safety.
Digestive System Diseases
A large portion of the trials target inflammatory bowel diseases and acid‑related disorders of the upper gastrointestinal tract.
- Moderate‑to‑severe Crohn’s disease
- Ulcerative colitis (including severe forms)
- Erosive esophagitis due to gastroesophageal reflux disease
- Endoscopic response and clinical remission endpoints
Researchers assess biologics like mirikizumab and oral agents such as etrasimod to see if they can induce remission, heal esophageal lesions, and improve patients’ quality of life.
Immune System Diseases
The center explores immune‑modulating strategies for a range of conditions where the immune response plays a central role.
- Inflammatory bowel disease (Crohn’s and ulcerative colitis)
- Immune‑mediated inflammation in gastrointestinal tract
- Vaccine‑driven protection against invasive bacterial pathogens
Trials include novel agents such as obefazimod and SAR441566, as well as an investigational vaccine (ExPEC9V) designed to stimulate protective immunity against pathogenic Escherichia coli.
Bacterial Infections and Mycoses
PreventaMed s.r.o. participates in studies aimed at preventing serious bacterial infections, especially those caused by extraintestinal pathogenic E. coli.
- Invasive extraintestinal pathogenic Escherichia coli disease
- History of recurrent urinary tract infections
- Vaccine‑induced microbiological protection
The primary goal is to evaluate whether the ExPEC9V vaccine can reduce the incidence of first invasive infection events in high‑risk adults.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 72 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 72 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in PreventaMed s.r.o.
lock Showing 1 of 50 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2) | Morphic Therapeutic Inc. | Phase II | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 72 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 4 | Unknown | 2023-08-02 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.